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Abstract
Aims/hypothesis The aim of this study was to compare the
pharmacokinetics of two different concentrations of insulin
aspart (B28Asp human insulin) in children aged 3–6 years
with type 1 diabetes.
Methods Young children with type 1 diabetes underwent
an open-label, randomised, two-period crossover study
in a clinical research facility, 2–6 weeks apart. In ran-
dom order, diluted (1:5 dilution with saline [154 mmol/l
NaCl]; 20 U/ml) or standard strength (100 U/ml) insulin
aspart was administered via an insulin pump as a meal
bolus and then overnight by closed-loop insulin delivery
as determined by a model predictive algorithm. Plasma
insulin was measured every 30–60 min from 17:00 hours
on day 1 to 8:00 hours on day 2. We measured the
time-to-peak insulin concentration (tmax), insulin meta-
bolic clearance rate (MCRI) and background insulin
concentration (insc) using compartmental modelling.
Results Eleven children (six male; age range 3.75–6.96 years,
HbA1c 7.6%±1.3% [60±14 mmol/mol], BMI standard devi-
ation score 1.0±0.8, duration of diabetes 2.2±1.0 years, total
daily dose 12.9 [10.6–16.5] U, fasting C-peptide concentra-
tion 5 [5–17.1] pmol/l; mean±SD or median [interquartile
range]) participated in the study. No differences between
standard and diluted insulin were observed in terms of tmax
(59.2±14.4 vs 61.6±8.7) min for standard vs diluted, p=0.59;
MCRI (1.98×10
−2±0.99×10−2 vs 1.89×10−2±0.82×10−2
1/kg/min, p=0.47), and insc (34 [1–72] vs 23 [3–65] pmol/l,
p=0.66). However, tmax showed less intersubject variability
following administration of diluted aspart (SD 14.4 vs
8.7 min, p=0.047).
Conclusions/interpretation Diluting insulin aspart does not
change its pharmacokinetics. However, it may result in less
variable absorption and could be used in young children with
type 1 diabetes undergoing closed-loop insulin delivery.
Trial registration: Clinicaltrials.gov NCT01557634
Funding: Funding was provided by the JDRF, 7th Framework
Programme of the European Union, Wellcome Trust Strategic
Award and the National Institute for Health Research
Cambridge Biomedical Research Centre.
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Introduction
Rapid-acting insulin analogues are commonly selected for
insulin pump therapies to achieve more physiological post-
prandial insulin levels. Further acceleration of absorption is
desirable to reduce postprandial glucose excursions, which are
often followed by late postprandial hypoglycaemia, and to
improve the performance of closed-loop insulin delivery sys-
tems [1]. This may be particularly relevant in younger children,
where postprandial swings in glucose levels may be greater
and the consequences of hypoglycaemia may be severe.
Diluting regular human insulin may accelerate its absorp-
tion [2, 3] although the exact mechanism responsible for this is
unknown. The formation of hexamers may be reduced, thus
promoting absorption from the subcutaneous depot to the
surrounding capillary bed. Rapid-acting insulin analogues
prevent the formation of hexamers and generally provide
more favourable pharmacokinetics [3]. However, little is
known about whether dilution affects insulin analogue absorp-
tion. An exploratory study in pigs showed no difference in the
absorption of insulin aspart (B28Asp human insulin) at three
different concentrations delivered via an insulin pump [4], but
no human studies have been reported. The objective of the
present study was to evaluate aspart pharmacokinetics in
young children following the administration of standard
strength (100 U/ml) and diluted (20 U/ml) insulin.
Methods
Participants We analysed data from 11 pump-treated children
with type 1 diabetes (six male, age 5.07±1.12 years [range
3.75–6.96 years], HbA1c 7.6%±1.3% (60±14 mmol/mol),
BMI standard deviation score 1.0±0.8 [range −0.55 to 2.11],
duration of diabetes 2.2±1.0 years [range 0.7–3.7 years], total
daily dose 12.9 [10.6–16.5] U/day and 0.65 [0.59–0.69] U/kg/
day; median [interquartile range (IQR)]) participating in a study
evaluating closed-loop insulin delivery [5]. Electronic supple-
mentary material (ESM) Fig. 1 shows the flow of participants
through the study. All participants agreed to take part in the
study and their parent or carer provided informed consent prior
to the commencement of clinical trials. The studywas approved
by the Cambridge Central Research Ethics Committee.
Study protocol Children were admitted in the afternoon on
two study visits, 2–6 weeks apart, at the Wellcome Trust
Clinical Research Facility, Addenbrooke’s Hospital,
Cambridge, to undergo closed-loop insulin delivery from
17:00 hours until 8:00 hours the following morning. On both
occasions, the children consumed identical evening meals at
17:00 hours [44±12 g carbohydrate] and optional bedtime
snacks [6±7 g carbohydrate]. Standard pump bolus calcula-
tors were used to calculate meal insulin boluses and basal rates
on the insulin pump (Animas 2020, Johnson & Johnson, PA,
USA) were adjusted every 15 min according to the output of a
model predictive control algorithm [6] informed by real-time
continuous glucose monitoring values (DexcomG4, Dexcom,
CA, USA). Standard strength (100 U/ml) insulin aspart (Novo
Nordisk, Bagsvaerd, Denmark) was infused at one visit and
diluted aspart (0.9% saline [154 mmol/l NaCl] at 1:5 ratio,
20 U/ml) was administered at the other; the order of the two
interventions was random. During closed-loop administration
of diluted insulin, the pump settings were changed by multi-
plying the current settings by a factor of five, and the revised
settings were entered into the computer running the closed-
loop algorithm.
Insulin and C-peptide measurement Venous blood samples
were taken at −30, 0, 30, 60, 90, 120, 180, 240, 300, 360,
420, 480, 540, 600, 660, 720, 780, 840 and 900 min relative to
17:00 hours for measuring the plasma insulin concentration.
Plasma was separated by centrifugation immediately after
sampling. Plasma insulin was measured using an
immunochemiluminometric assay (Invitron, Monmouth,
UK; intra-assay CV 4.7%, interassay CV 7.2–8.1%; 100%
cross reactivity with insulin aspart). Fasting C-peptide levels
were measured at plasma glucose values above 6 mmol/l by
ELISA (Mercodia, Uppsala, Sweden).
Pharmacokinetics Aspart pharmacokinetics was assessed
using a two-compartment model [7, 8] measuring the time-to-
peak of plasma insulin concentration (tmax), metabolic clearance
rate of insulin (MCRI), and background plasma insulin concen-
tration (insc). The three parameters were estimated by fitting a
Bayesian statistical model to plasma insulin data (ESM
Methods). The compartmental model was implemented using
WinBUGS software version 1.4 (MRC Biostatistics Unit,
Cambridge, UK) [9] with a WBDev interface (MRC
Biostatistics Unit). The insulinmeasurement error was assumed
to be uncorrelated and normally distributed, with a CVof 6%.
Statistical analysis Differences between pharmacokinetic pa-
rameters were assessed by paired t test (for normally distrib-
uted variables) or the Wilcoxon signed-rank test (for non-
normally distributed variables). Levene’s test was used to
assess the equality of variances of parameter estimates. The
Spearman’s rank correlation evaluated correlations between
pharmacokinetic and demographic indices. A p value of <0.05
was considered statistically significant. Values are presented
as the mean±SD or the median (IQR) unless stated otherwise.
Results
Figure 1 demonstrates a model fitted to the plasma insulin
concentration in a sample participant (ESM Fig. 2). Plasma
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insulin increased rapidly after a prandial insulin bolus and
then decreased to basal levels and was variable overnight,
reflecting insulin delivery informed by the control algorithm.
Weighted residuals demonstrated an overall good and unbi-
ased fit across all participants (ESM Fig. 3).
Table 1 shows the estimates of three pharmacokinetic pa-
rameters (tmax, MCRI and insc) measured after standard
strength and diluted insulin aspart administration. No differ-
ences between the two preparations were observed. However,
a smaller intersubject variability in tmax was observed follow-
ing the administration of diluted insulin (SD 14.4 vs 8.7 min,
standard vs diluted; p=0.047).
Relationships between the pharmacokinetic parameters and
demographic variables are shown in ESM Table 1. The insc
parameter, but not the others, correlated positively with the
insulin total daily dose (rs=0.71, p=0.014), but not with the
fasting C-peptide concentration (rs=−0.19, p=0.39; C-peptide
concentration 5 [3.7–17.1] pmol/l, median [IQR]), suggesting
that the insc does not reflect residual insulin secretion.
Discussion
Our data from a randomised, two-period crossover study
comparing closed-loop insulin delivery using diluted vs stan-
dard insulin aspart in young children with type 1 diabetes
suggest no significant differences in aspart pharmacokinetics
between the two strengths except for reduced intersubject
variability in tmax following administration of diluted aspart.
The mean value of tmax in the present study (60.4 min) is
comparable with that reported in older children and adults with
type 1 diabetes following insulin bolus injection (49 min) [10]
or during closed-loop insulin delivery (66 min and 51 min,
respectively) [7, 8]. Similar estimates of MCRI and insc were
also found in the current study and published literature (1.94
vs 1.68×10−2 vs 1.90×10−2 1/kg/min for MCRI, 29 vs 28 vs
61 pmol/l for insc) [7, 8]. In the present study,MCRI values in
the two visits were highly correlated (r=0.918, p<0.001), as
were the insc values (rs=0.964, p<0.001), indicating that
these characteristics are reproducible even with diluted insulin.
However, this association was not found for tmax (p=0.4).
Our main finding that no difference in aspart pharmacoki-
netics exists between standard-strength and diluted insulin
administered to young children is consistent with Petersen
et al, who demonstrated no significant difference between
U200, U100 and U20 in terms of insulin aspart pharmacoki-
netics during continuous subcutaneous insulin infusion in pigs
[4]. Theoretical calculations considering hexamer, dimer and
monomer formation and absorption characteristics also sug-
gested no effect of dilution on the absorption of rapid-acting
insulin analogues [11]; in contrast, diluted regular insulin is
absorbed more rapidly in humans [3].
We show less variable absorption of diluted insulin, based
on a difference in the intersubject variability of tmax. The
origin of such reduced variability is unclear. We hypothesise
that it may be related to fewer mechanical pump delivery
errors and more consistent absorption from the insulin depot
because of its larger size. The lower absorption variability
might benefit young children by allowing caregivers to more
confidently predict the timing of onset and the duration of
insulin action, and providing more consistent glycaemic re-
sults during closed-loop insulin delivery.
Our data suggest that background insc does not reflect
residual insulin secretion, as hypothesised previously [7]. In
the present study, the fasting C-peptide concentration was
Fig. 1 Model fit to plasma insulin concentration in a sample participant
during the delivery of diluted (a) and standard strength (b) insulin.
Evening meals were consumed at time 0 and were accompanied by split
prandial insulin boluses, indicated by blue arrows. The dotted vertical line
indicates time that closed-loop delivery started. The red solid line shows
the median of the fitted model. The blue dashed lines show the 95%
credible interval of the fitted model. The solid blue line shows insulin
infusion
Table 1 Comparison of parameter estimates between diluted and stan-
dard strength insulin delivery
Model
parameters
Standard strength
insulin 100 U/ml
(N=11)
Diluted insulin
20 U/ml (N=11)
p value
tmax (min) 59.2±14.4 61.6±8.7 0.59
a
MCRI (10
−2×1/kg/min) 1.98±0.99 1.89±0.82 0.47a
insc (pmol/l) 34 (1–72) 23 (3–65) 0.66
b
a Paired t test; data are means±SD
bWilcoxon signed rank test; data are medians (IQR)
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lower than the detection limit of 5 pmol/l in more than half of
the participants, and did not correlate with insc. However, the
significant positive correlation between insc and the total daily
insulin dose suggests that the background insulin level may
result from a slowly absorbing insulin pool in the subcutane-
ous insulin depot, where the amount of ‘residual’ insulin is
proportional to one’s total daily dose. However, this hypoth-
esis is derived from our retrospective analysis on data from a
limited sample size and further investigations are warranted.
The strength of our study is the evaluation of insulin
kinetics in an underserved population of young children with
type 1 diabetes who may benefit from insulin dilution through
reduced variability in insulin absorption. The limitations are
the relatively small size of the study and the use of saline
instead of a proprietary diluter, which is not generally avail-
able. The sampling frequency of 30–60 min is lower than that
used by others [2], but this is compensated for by longer visits
and the dynamic nature of insulin delivery which enables
accurate parameter estimates to be obtained, as demonstrated
by computer simulations (ESM Simulation analysis).
In conclusion, we found no significant change in pharma-
cokinetics when using diluted aspart. However, diluting aspart
may lead to less variable absorption and could be beneficial to
young children with type 1 diabetes undergoing closed-loop
insulin delivery.
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